Biogen

Company Overview

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.

Industry

Biotechnology

Financial Summary

Revenue (TTM)

$10.17B

Net Income (TTM)

$3.05B

Total Assets

$26.84B

Total Debt

$6.30B

Total Equity

$13.40B

Market Cap

-

Valuation Metrics

P/E Ratio

-

P/B Ratio

-

Profit Margin

29.95%

ROE

22.74%

ROA

11.35%

Dividend Yield

-

More Health Care Stocks